Brief: ACELYRIN Confirms Receipt Of Unsolicited Indication Of Interest From Concentra Biosciences
21/02/2025 02:06
Feb 20 (Reuters) -
* ACELYRIN CONFIRMS RECEIPT OF UNSOLICITED INDICATION OF
INTEREST
FROM CONCENTRA BIOSCIENCES
Source text: ID:nGNXcfV0lM
Further company coverage: ALMS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial